Literature DB >> 2013839

Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.

G M Pollack1, K L Brouwer.   

Abstract

The potential influence of alterations in several physiologic processes (hepatocellular egress, biliary excretion, gastrointestinal transit) and biotransformation steps (oxidative metabolism, glucuronidation) on the disposition of agents subject to significant enterohepatic recirculation (ER) via the glucuronide conjugate was examined in a series of simulation experiments. The model of ER developed was based upon the disposition of valproic acid (VPA) and valproate glucuronide (VPA-G) in the rat. The systemic disposition of VPA was simulated following changes in several processes contributing to (or competing with) ER: hepatic oxidative metabolism, hepatic glucuronidation, sinusoidal egress of glucuronide conjugate, canalicular egress of glucuronide conjugate, and gastrointestinal transit. Changes in the formation clearance of VPA-G resulted in a less than proportional change in systemic clearance of VPA, whereas changes in oxidative metabolism led to a greater than proportional change in systemic clearance. Furthermore, alterations in hepatocellular egress of VPA-G affected the disposition of the parent compound, suggesting that drug interactions or disease state effects on metabolite transport may be misinterpreted as effects at the level of metabolite formation. Analytical methods are proposed to recover the intrinsic kinetic parameters (formation clearances of metabolites, renal clearance of parent, volume of distribution) in the presence of ER from the systemic disposition of the parent alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013839     DOI: 10.1007/bf01073869

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  25 in total

1.  Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat.

Authors:  K Singh; J M Orr; F S Abbott
Journal:  Drug Metab Dispos       Date:  1988 Nov-Dec       Impact factor: 3.922

2.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

3.  Time-delay for two-compartment models used for study of enterohepatic circulation of drugs.

Authors:  Y Plusquellec; L Bousquet
Journal:  IEEE Trans Biomed Eng       Date:  1984-06       Impact factor: 4.538

4.  A time-lag model for pharmacokinetics of drugs subject to enterohepatic circulation.

Authors:  J L Steimer; Y Plusquellec; A Guillaume; J F Boisvieux
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

5.  A liner mode of reversible metabolism and its application to bioavailability assessment.

Authors:  S Hwang; K C Kwan; K S Albert
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

6.  Estimating the fraction reabsorbed in drugs undergoing enterohepatic circulation.

Authors:  F L Tse; F Ballard; J Skinn
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

7.  Alteration of methotrexate metabolism in rats by administration of an elemental liquid diet. I. Changes in drug enterohepatic circulation.

Authors:  O J McAnena; M Rossi; B M Mehta; J M Daly
Journal:  Cancer       Date:  1987-01-01       Impact factor: 6.860

8.  Metabolism and enterohepatic circulation of benzo(a)pyrene-4,5-epoxide in the rat.

Authors:  T R Elmhirst; J K Chipman; O Ribeiro; P C Hirom; P Millburn
Journal:  Xenobiotica       Date:  1985-11       Impact factor: 1.908

9.  Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat.

Authors:  B E Dahlström; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

10.  Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect.

Authors:  R J Herman; J D Van Pham; C B Szakacs
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

View more
  7 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-09       Impact factor: 2.745

3.  Influence of enterohepatic recycling on the time course of brain-to-blood partitioning of valproic acid in rats.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2012-06-19       Impact factor: 3.922

4.  Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.

Authors:  S Kojima; M Nadai; K Kitaichi; L Wang; T Nabeshima; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

5.  Age-dependent intestinal absorption of valproic acid in the rat.

Authors:  A Cato; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

6.  Sex related differences on valproic acid pharmacokinetics after oral single dose.

Authors:  Manuel Ibarra; Marta Vázquez; Pietro Fagiolino; Hartmut Derendorf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-20       Impact factor: 2.745

7.  Enteric reabsorption processes and their impact on drug pharmacokinetics.

Authors:  Manuel Ibarra; Iñaki F Trocóniz; Pietro Fagiolino
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.